The ESPOIR cohort: A ten-year follow-up of early arthritis in France: Methodology and baseline characteristics of the 813 included patients

被引:143
作者
Combe, Bemard
Benessiano, Joealle
Berenbaum, Francis
Cantagrel, Alain
Daures, Jean-Pierre
Dougados, Maxime
Fardellone, Patrice
Fautrel, Bruno
Flipo, Rene-Marc
Goupille, Philippe
Guillemin, Francis
Le Loet, Xavier
Logeart, Isabelle
Marlette, Xavier
Meyer, Olvier
Ravaud, Philippe
Rincheval, Nathalle
Saraux, Alain
Schaeverbeke, Thierry
Sibilia, Jean
机构
[1] Univ Hosp, Montpellier, France
[2] Hop Xavier Bichat, Paris, France
[3] St Antoine Univ Hosp, Paris, France
[4] Univ Hosp, Toulouse, France
[5] Descartes Univ, Cochin Hosp, UPRES EA 4058, Paris, France
[6] Univ Hosp, Amiens, France
[7] Pitie Salpetriere Univ Hosp, Paris, France
[8] Univ Hosp, Lille, France
[9] Univ Hosp, Tours, France
[10] Univ Hosp, INSERM, C1E6, Nancy, France
[11] Univ Hosp, Rouen, France
[12] MSD, Paris, France
[13] Paris Sud Univ Hosp, Le Kremlin Bicetre, France
[14] Univ Hosp, Brest, France
[15] Univ Hosp, Bordeaux, France
[16] Univ Hosp, Strasbourg, France
关键词
ESPOIR cohort; rheumatoid arthritis; early arthritis; undifferentiated arthritis;
D O I
10.1016/j.jbspin.2007.06.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The French Society of Rheumatology initiated a large national multicenter, longitudinal and prospective cohort, the so-called "ESPOIR cohort study" in order to set up databases to allow various investigations on diagnosis, prognostic markers, epidemiology, pathogenesis and medico-economic factors in the field of early arthritis and rheumatoid arthritis. Methods: Patients were recruited if they had undifferentiated arthritis or rheumatoid arthritis, of less than 6 months disease duration and if they were DMARD and steroids naive. Patients have then to be followed every 6 months during the first 2 years then every year during at least 10 years. Clinical, biological. radiographic and medico-economic databases have been constituted to fit in the different objectives of the project and more than 20 scientific studies have already been accepted by the scientific committee. Results: 813 patients were included (76.75% were female). The mean age was 48.07 +/- 12.55 years. The mean delay from the onset of symptoms to referral to the rheumatologist was 74.8 +/- 76.6 days. Baseline swollen and tender joint counts were 7.19 +/- 5.37 and 8.43 +/- 7.01; DAS28 score was 5.11 +/- 1.31. CRP was abnormal in 38.9% of the patients; 44.2%, 45.8% and 38.8% had respectively IgM rheumatoid factor (RF), IgA RF and anti-CCP antibodies. HLA DRB 1 *01 or 04 genes were found in 56.7% of them. Finally, 22% of these patients had erosions on hand or feet at baseline. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:440 / 445
页数:6
相关论文
共 39 条
  • [1] The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study
    Barrett, EM
    Scott, DGI
    Wiles, NJ
    Symmons, DPM
    [J]. RHEUMATOLOGY, 2000, 39 (12) : 1403 - 1409
  • [2] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    Breedveld, FC
    Weisman, MH
    Kavanaugh, AF
    Cohen, SB
    Pavelka, K
    van Vollenhoven, R
    Sharp, J
    Perez, JL
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (01): : 26 - 37
  • [3] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
    Clair, EWS
    van der Heijde, DMFM
    Smolen, JS
    Maini, RN
    Bathon, JM
    Emery, P
    Keystone, E
    Schiff, M
    Kalden, JR
    Wang, B
    DeWoody, K
    Weiss, R
    Baker, D
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3432 - 3443
  • [4] EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    Combe, B.
    Landewe, R.
    Lukas, C.
    Bolosiu, H. D.
    Breedveld, F.
    Dougados, M.
    Emery, P.
    Ferraccioli, G.
    Hazes, J. M. W.
    Klareskog, L.
    Machold, K.
    Martin-Mola, E.
    Nielsen, H.
    Silman, A.
    Smolen, J.
    Yazici, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) : 34 - 45
  • [5] Combe B, 2003, J RHEUMATOL, V30, P2344
  • [6] Combe B, 2001, ARTHRITIS RHEUM, V44, P1736, DOI 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO
  • [7] 2-I
  • [8] Cunnane G, 2001, ARTHRITIS RHEUM-US, V44, P1744, DOI 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO
  • [9] 2-K
  • [10] Dellhag B, 1999, ARTHRIT CARE RES, V12, P33, DOI 10.1002/1529-0131(199902)12:1<33::AID-ART6>3.0.CO